Trial Profile
A pilot safety and dose-finding trial of intravenous recombinant human relaxin (rhRlx) in compensated congestive heart failure.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2013
Price :
$35
*
At a glance
- Drugs Serelaxin (Primary)
- Indications Heart failure
- Focus Pharmacodynamics
- 23 Apr 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
- 18 Oct 2006 New trial record.